BP11119 PLGA 65:35, Lauryl Ester Terminated, IV ≤ 0.08 dl/g, Mw ≤ 5 kDa

PLGA 65:35, Lauryl Ester Terminated, IV ≤ 0.08 dl/g, Mw ≤ 5 kDa Description

PLGA 65:35, Lauryl Ester Terminated, IV ≤ 0.08 dl/g, Mw ≤ 5 kDa is a biodegradable copolymer synthesised with a 65:35 lactide to glycolide ratio and functionalised with lauryl ester end groups. The specified intrinsic viscosity and molecular weight are critical parameters influencing polymer chain length and degradation kinetics. These characteristics directly affect solvent processing, film formation, and in vivo performance, making the material suitable for precise biomedical applications such as controlled drug delivery systems.

PLGA 65:35, Lauryl Ester Terminated, IV ≤ 0.08 dl/g, Mw ≤ 5 kDa Applications

Healthcare Applications
   - Use as a drug encapsulation matrix in implantable devices to achieve controlled therapeutic release by utilising its tailored degradation profile.
   - Applied as a scaffold in tissue engineering to support cellular integration and gradual material resorption through predictable hydrolysis.

Biotechnology Applications
   - Employed in microsphere fabrication for sustained release formulations, where the polymer's modified degradation rate ensures extended release of active agents.
   - Utilised in coating applications for biomedical devices to enhance biocompatibility and modulate surface interactions.

PLGA 65:35, Lauryl Ester Terminated, IV ≤ 0.08 dl/g, Mw ≤ 5 kDa Packing

The polymer is packaged in sealed, inert containers designed to minimise moisture exposure and contamination risks. Protective measures, including inner lining and desiccant incorporation, are applied to maintain polymer stability during storage and transit. Storage under controlled ambient temperature and humidity conditions is advised. Custom packaging options, such as vacuum-sealed pouches or secondary containment, are available based on specific handling requirements.

Additional Information

PLGA copolymers have been extensively studied in the biomedical field due to their biodegradability and adjustable degradation profiles. Their performance is highly influenced by copolymer ratios and end-group modifications, which dictate hydrolysis behaviour and material processing properties. Researchers use a variety of analytical techniques to refine synthesis processes and ensure reproducible results.

Understanding the material properties of PLGA is essential for optimising its application in drug delivery and tissue engineering. Its predictable in vivo degradation, when paired with precise molecular characterisation methods, supports the development of formulations with controlled release profiles and enhanced biocompatibility.

Regulatory Note: This material is intended for industrial and research applications. It is the customer's responsibility to ensure compliance with all relevant safety and regulatory standards in their intended use.